Fosun Pharma to acquire Henlius for HKD5.4bn.

Fosun Pharma, a Chinese listed pharmaceutical company, offered to acquire Henlius, a global biopharmaceutical company, for HKD5.4bn. Henlius, as a core innovative asset of Fosun Pharma, will benefit from sustainable growth and enhance Fosun Pharma’s strategic goals in the innovative biopharmaceutical sectors upon the completion of the transaction.